363 related articles for article (PubMed ID: 23875845)
1. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
Labrador-Horrillo M; Valero A; Velasco M; Jáuregui I; Sastre J; Bartra J; Silvestre JF; Ortiz de Frutos J; Gimenez-Arnau A; Ferrer M
Expert Opin Biol Ther; 2013 Sep; 13(9):1225-8. PubMed ID: 23875845
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in chronic urticaria: a retrospective series of 15 cases.
Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E
Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
7. Chronic idiopathic urticaria: treatment with omalizumab.
Naaman S; Sussman G
Skin Therapy Lett; 2014; 19(6):1-4. PubMed ID: 25807072
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
9. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
Metz M; Ohanyan T; Church MK; Maurer M
JAMA Dermatol; 2014 Mar; 150(3):288-90. PubMed ID: 24477320
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab in chronic urticaria.
Metz M; Maurer M
Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
[TBL] [Abstract][Full Text] [Related]
11. Real-life experiences with omalizumab for the treatment of chronic urticaria.
Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
Wieder S; Maurer M; Lebwohl M
Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
[TBL] [Abstract][Full Text] [Related]
13. Therapy of chronic urticaria: a simple, modern approach.
Kaplan AP
Ann Allergy Asthma Immunol; 2014 May; 112(5):419-25. PubMed ID: 24656924
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
Har D; Patel S; Khan DA
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):126-9. PubMed ID: 26093778
[TBL] [Abstract][Full Text] [Related]
15. Biologic agents and the therapy of chronic spontaneous urticaria.
Kaplan AP; Popov TA
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):347-53. PubMed ID: 24936849
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
17. Extraordinary response to omalizumab in a child with severe chronic urticaria.
Asero R; Casalone R; Iemoli E
Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):41-2. PubMed ID: 24702874
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey.
Büyüköztürk S; Gelincik A; Demirtürk M; Kocaturk E; Colakoğlu B; Dal M
J Dermatol; 2012 May; 39(5):439-42. PubMed ID: 22221177
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
20. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
Kai AC; Flohr C; Grattan CE
Clin Exp Dermatol; 2014 Jul; 39(5):651-2. PubMed ID: 24758481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
